Adherence, acceptability and tolerability of venlafaxine extended release at dose of 300 mg/day in patients with major depressive disorder.

Adherence to antidepressants is essential for good outcomes when treating depressive disorders.

Adherencia al tratamiento, aceptabilidad y tolerabilidad de venlafaxina XR a dosis de 300 mg/día en pacientes con trastorno depresivo mayor / Adherence, acceptability and tolerability of venlafaxine extended release at dose of 300 mg/ day in patients with major depressive disorder

Introducción. La adherencia a los antidepresivos es fundamental para obtener buenos resultados en el tratamiento de la depresión. El objetivo del actual estudio fue evaluar la adherencia, aceptabilidad y tolerabilidad de venlafaxina XR a dosis de 300 mg/día, administrada en uno o dos comprimidos, tras un periodo de tratamiento de 6 ± 2 meses en pacientes con trastorno depresivo mayor (TDM). Metodología. Estudio observacional, transversal, de práctica clínica habitual en el que participaron 590 pacientes con TDM que asistían a consultas de centros públicos o privados de toda España, de los cuales 361 y 229 recibieron uno (300 mg) o dos comprimidos (150+150 mg o 225+75 mg) de venlafaxina XR, respectivamente. Los datos del estudio se obtuvieron de la entrevista con el paciente, de la historia clínica y de cuestionarios validados. Resultados. El método Haynes-Sackett y el cuestionario de Morisky-Green revelaron que la adherencia al tratamiento fue similar en ambos grupos. Los pacientes que recibieron la dosis de venlafaxina XR en un comprimido mostraron mayor satisfacción con el tratamiento según el cuestionario TSQM9. La escala MADRS reveló que en el 23% de los pacientes el TDM había remitido, y solo en el 9% se mantenía grave, en el 26% era moderado y en el 42% leve. Igual resultado se obtuvo con el cuestionario PHQ-9. En general, los pacientes mostraron buena tolerabilidad a la venlafaxina XR a dosis altas con las dos pautas de administración, y los efectos adversos más comunes fueron la disfunción sexual, sudoración y estreñimiento. Conclusiones. La adherencia al tratamiento con venlafaxina XR de 300 mg/día en uno o dos comprimidos fue similar. Los pacientes que recibieron un solo comprimido mostraron mayor satisfacción con el tratamiento. El perfil de seguridad de venlafaxina XR 300 mg fue favorable. No se produjeron abandonos, ni elevaciones clínicamente significativas de la presión arterial que condicionaran la pauta de uso. (AU)

Background. Adherence to antidepressants is essential for good outcomes when treating depressive disorders. The objective of the current study was to evaluate the adherence, acceptability and tolerability of venlafaxine XR at a dose of 300 mg/day, administered in one or two tablets, after a treatment period of 6 ± 2 months in patients with major depressive disorder (MDD). Subjects and methods. Observational, cross-sectional study of routine clinical practice in 590 outpatients with MDD who attended at public or private centers all over country, of whom 361 and 229 received one (300 mg) or two tablets (150+150 mg o 225+75 mg) of venlafaxine XR, respectively. The study data were obtained from the interview with the patient, the clinical history and validated questionnaires. Results. The Haynes-Sackett method and the MoriskyGreen questionnaire revealed that adherence to treatment was similar in both groups. The patients who received the dose of venlafaxine XR in one tablet showed greater satisfaction with the treatment according to the TSQM-9 questionnaire. The MADRS scale revealed that in 23% of the patients the MDD had remitted, and only in 9% it remained severe, in 26% it was moderate and in 42% mild. The same result was obtained with the PHQ-9 questionnaire. In general, the patients showed good tolerability to high doses of venlafaxine XR with both dosing regimens, and the most common adverse effects were sexual dysfunction, sweating and constipation. Conclusions. Adherence to treatment with venlafaxine XR 300 mg/day in one or two tablets was similar. Patients who received a single tablet showed greater satisfaction with the treatment. The safety profile of high dose venlafaxine was favorable and there was dropouts or clinically significant elevations that affected the dosing regimen. (AU)

The Combined Effect of Mediterranean Shrubland Pasture and the Dietary Administration of Sage By-Products on the Antioxidant Status of Segureña Ewes and Lambs.

The objective of this study was to determine if the combined effect of ewe grazing and the incorporation of sage by-products in the lamb feed enhances the Segureña ewe and lamb antioxidant status. For that, the endogenous (related to blood antioxidant enzymes) and exogenous (plasma antioxidant activity) antioxidant systems of ewes and lambs were studied at the physiological stages of lactation, after weaning and at the end of the fattening period. Major results indicated that grazing improved the enzymatic antioxidant defense of ewes during the stressful period of lamb weaning, and also, the antioxidant status of the ewe plasma at both physiological stages: lactation and after lamb weaning. With regards to the lambs, ewe grazing stimulated the antioxidant enzymatic defense during lactation, but not the antioxidant capacity of the plasma. At the end of the fattening period, the inclusion of sage by-products in the lamb diet (10% w/w) enhanced both the enzymatic cascade and antioxidant capacity of the lamb plasma. The antioxidant capacity of the lamb meat was also studied and the benefits of sage were detected in samples from the deltoideus muscle. Thus, Mediterranean grazing stimulated the antioxidant defense in ewes, while the inclusion of sage by-products in the lamb diets enhanced the antioxidant status of both blood and meat.

Efecto de los síntomas psiquiátricos y calidad de vida sobre el desempeño cognitivo en el VHC / Effect of psychiatric symptoms and quality of life on cognitive performance in HCV patients

OBJETIVO: El virus de la hepatitis C (VHC) se ha relacionado repetidamente con un peor rendimiento de las funciones cognitivas. Sin embargo, no existe consenso acerca de la gravedad o del tipo de afectación cognitiva. Además, rara vez se controlan las variables que puedan influir en ello. El objetivo del presente estudio es definir el perfil cognitivo de los pacientes con VHC tras controlar el efecto de posibles covariables. MÉTODOS: Se dividió a 42 pacientes con VHC en 2 grupos según la existencia de coinfección con virus de la inmunodeficiencia humana y se incluyó a un tercer grupo de 22 controles sanos. La evaluación neuropsicológica incluyó medidas de velocidad de procesamiento, funciones ejecutivas, memoria verbal, memoria visual y memoria de trabajo. Para explorar diferencias e identificar posibles covariables se tomaron medidas de depresión (BDI), ansiedad (HAM-A), fatiga (MAF), anhedonia (PAS), insomnio (ISI), calidad de vida (SF-36) y antecedentes de consumo de drogas (DAST-20). RESULTADOS: Los pacientes con VHC (incluyendo coinfectados por virus de la inmunodeficiencia humana) tuvieron un rendimiento peor que el grupo control en todos los dominios cognitivos. Sin embargo, tras controlar el efecto de BDI, HAM-A, MAF, ISI, SF-36 y DAST-20, solo la memoria verbal de los pacientes con VHC mostró diferencias entre los grupos. CONCLUSIONES: En consonancia con estudios previos, nuestros resultados muestran una relación entre la memoria verbal y el efecto del VHC en el cerebro, aunque el presente estudio no ha podido relacionar la afectación frontoestriatal de los pacientes con VHC con su rendimiento cognitivo

OBJECTIVE: Reduced performance in several cognitive domains has been repeatedly related to hepatitis C virus (HCV). Nevertheless, there is no consensus about the severity or cognitive profile. Moreover, other possible influential variables are scarcely controlled. The aim of this study is to define the specific cognitive profile in HCV after controlling for confounding variables. METHODS: Forty-two HCV patients were distributed in 2groups according to the presence of co-infection with human immunodeficiency virus; a third group with 22 healthy controls was also included. The neuropsychological assessment included tests that assess processing speed, executive functioning, verbal memory, visual memory and working memory. Measures of depression (BDI), anxiety (HAM-A), fatigue (MAF), anhedonia (PAS), insomnia (ISI), quality of life (SF-36) and history of drug abuse (DAST-20) were taken in order to explore differences among groups and to control for their possible influence on cognitive performance. RESULTS: HCV patients (including human immunodeficiency virus-coinfection) performed significantly worse in all cognitive measures. However, when the effect of BDI, HAM-A, MAF, ISI, SF-36 & DAST-20 was controlled, only verbal memory of HCV patients differed among groups. Coinfected patients performed worse in verbal memory. CONCLUSIONS: According to previous studies verbal memory is the unique cognitive domain related to the effect of HCV. The present study does not support that the neurovirulence effect of HCV is decreasing cognitive performance in HCV patients. Nevertheless, the present study cannot relate the fronto-striatal disruption with the cognitive performance in HCV patients

Effect of psychiatric symptoms and quality of life on cognitive performance in HCV patients. / Efecto de los síntomas psiquiátricos y calidad de vida sobre el desempeño cognitivo en el VHC.

OBJECTIVE: Reduced performance in several cognitive domains has been repeatedly related to hepatitis C virus (HCV). Nevertheless, there is no consensus about the severity or cognitive profile. Moreover, other possible influential variables are scarcely controlled. The aim of this study is to define the specific cognitive profile in HCV after controlling for confounding variables. METHODS: Forty-two HCV patients were distributed in 2groups according to the presence of co-infection with human immunodeficiency virus; a third group with 22 healthy controls was also included. The neuropsychological assessment included tests that assess processing speed, executive functioning, verbal memory, visual memory and working memory. Measures of depression (BDI), anxiety (HAM-A), fatigue (MAF), anhedonia (PAS), insomnia (ISI), quality of life (SF-36) and history of drug abuse (DAST-20) were taken in order to explore differences among groups and to control for their possible influence on cognitive performance. RESULTS: HCV patients (including human immunodeficiency virus-coinfection) performed significantly worse in all cognitive measures. However, when the effect of BDI, HAM-A, MAF, ISI, SF-36 & DAST-20 was controlled, only verbal memory of HCV patients differed among groups. Coinfected patients performed worse in verbal memory. CONCLUSIONS: According to previous studies verbal memory is the unique cognitive domain related to the effect of HCV. The present study does not support that the neurovirulence effect of HCV is decreasing cognitive performance in HCV patients. Nevertheless, the present study cannot relate the fronto-striatal disruption with the cognitive performance in HCV patients.

Influence of water stress and storage time on preservation of the fresh volatile profile of three basil genotypes.

The main goal of the present study was to describe the volatile profile of three different basil genotypes (Genovese and Green and Purple Iranian), and the impact that water stress (75% and 50% field capacity) and storage time (up to 7days) have under mild refrigerated conditions. The chromatographic profile pointed to three different chemotypes: linalool/eugenol, neral/geranial, and estragol, for Genovese, Green, and Purple genotypes, respectively. Water stress depleted the volatile profile of these three landraces, due to a reduction in the absolute concentrations of some of the components related to fresh aroma (linalool, nerol, geraniol and eugenol). The stability of the basil volatile profile during storage varied depending on the water stress that had been applied. Concentration reductions of close to 50% were quantified for most of the components identified in the Purple genotype.